📣 VC round data is live. Check it out!

Ryvu Therapeutics Valuation Multiples

Discover revenue and EBITDA valuation multiples for Ryvu Therapeutics and similar public comparables like Rallybio, PolyPid, Eurofins-Cerep, Prestige Biologics and more.

Ryvu Therapeutics Overview

About Ryvu Therapeutics

Ryvu Therapeutics SA is a company which is engaged in discovering and developing small molecule therapies that address oncology. Its product candidate SEL120, is a kinase inhibitor with potential for development in hematological malignancies and solid tumors. The pipeline products of the company are developed in the areas of kinases, cancer metabolism, synthetic lethality, and immuno-oncology pathways.


Founded

2007

HQ

Poland

Employees

294

Website

ryvu.com

Financials (LTM)

Revenue: $32M
EBITDA: ($14M)

EV

$92M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Ryvu Therapeutics Financials

Ryvu Therapeutics reported last 12-month revenue of $32M and negative EBITDA of ($14M).

In the same LTM period, Ryvu Therapeutics generated ($15M) in gross profit, ($14M) in EBITDA losses, and had net loss of ($17M).

Revenue (LTM)


Ryvu Therapeutics P&L

In the most recent fiscal year, Ryvu Therapeutics reported revenue of $23M and EBITDA of ($22M).

Ryvu Therapeutics is unprofitable as of last fiscal year, with gross margin of 56%, EBITDA margin of (96%), and net margin of (120%).

See analyst estimates for Ryvu Therapeutics
LTMLast FY202320242025202620272028
Revenue$32M$23M$13M$21M$17M
Gross Profit($15M)$13M$8M$16M$13M
Gross Margin(48%)56%63%75%76%
EBITDA($14M)($22M)($22M)($27M)($22M)
EBITDA Margin(43%)(96%)(173%)(124%)(131%)
EBIT Margin(52%)(115%)(208%)(156%)(156%)
Net Profit($17M)($28M)($25M)($31M)($28M)
Net Margin(52%)(120%)(197%)(143%)(163%)
Net Debt-$4M---

Financial data powered by Morningstar, Inc.

Ryvu Therapeutics Stock Performance

Ryvu Therapeutics has current market cap of $94M, and enterprise value of $92M.

Market Cap Evolution


Ryvu Therapeutics' stock price is $4.06.

Ryvu Therapeutics share price decreased by 10.9% in the last 30 days, and by 53.5% in the last year.

Ryvu Therapeutics has an EPS (earnings per share) of $-1.20.

See more trading valuation data for Ryvu Therapeutics
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$92M$94M-7.3%-10.9%-35.7%-53.5%$-1.20

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Ryvu Therapeutics Valuation Multiples

Ryvu Therapeutics trades at 2.9x EV/Revenue multiple, and (6.8x) EV/EBITDA.

See NTM and 2027E valuation multiples for Ryvu Therapeutics

EV / Revenue (LTM)


Ryvu Therapeutics Financial Valuation Multiples

As of June 3, 2026, Ryvu Therapeutics has market cap of $94M and EV of $92M.

Ryvu Therapeutics has a P/E ratio of (5.6x).

LTMLast FY202320242025202620272028
EV/Revenue2.9x4.0x7.2x4.3x5.4x
EV/EBITDA(6.8x)(4.1x)(4.1x)(3.5x)(4.1x)
EV/EBIT(5.6x)(3.5x)(3.4x)(2.8x)(3.5x)
EV/Gross Profit(6.1x)7.1x11.5x5.8x7.1x
P/E(5.6x)(3.4x)(3.7x)(3.1x)(3.4x)
EV/FCF(43.2x)(2.8x)(3.6x)(2.5x)(2.8x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Ryvu Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Ryvu Therapeutics Margins & Growth Rates

Ryvu Therapeutics grew revenue by 87% but EBITDA decreased by 116% in the last fiscal year.

In the most recent fiscal year, Ryvu Therapeutics reported gross margin of 56%, EBITDA margin of (96%), and net margin of (120%).

See estimated margins and future growth rates for Ryvu Therapeutics

Ryvu Therapeutics Margins

Last FY202420252026202720282029
Gross Margin56%75%76%1%
EBITDA Margin(96%)(124%)(131%)8%
EBIT Margin(115%)(156%)(156%)1%
Net Margin(120%)(143%)(163%)(1%)
FCF Margin(142%)(174%)(195%)93%

Ryvu Therapeutics Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth87%66%(20%)153%
Gross Profit Growth(96%)99%(19%)(96%)
EBITDA Growth(116%)19%(16%)(116%)
EBIT Growth(102%)25%(20%)(102%)
Net Profit Growth(98%)21%(9%)(98%)
FCF Growth(222%)45%(10%)(220%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Ryvu Therapeutics Operational KPIs

Ryvu Therapeutics' revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.1M for the same period.

Ryvu Therapeutics' Rule of 40 is 162% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Ryvu Therapeutics' Rule of X is 392% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Ryvu Therapeutics
LTMLast FY202320242025202620272028
Rule of 40(20%)162%---
Bessemer Rule of X14%392%---
Revenue per Employee-$0.1M---
Opex per Employee-$0.1M---
Opex to Revenue-171%270%231%232%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Ryvu Therapeutics Competitors

Ryvu Therapeutics competitors include Rallybio, PolyPid, Eurofins-Cerep, Prestige Biologics, Bioton, Rani Therapeutics, ProMIS Neurosciences, Nanexa, Laboratorios Richmond and Ensol Biosciences.

Most Ryvu Therapeutics public comparables operate across Biopharmaceuticals, BioTech and DeepTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Rallybio55.4x-(1.4x)-
PolyPid--(2.7x)-
Eurofins-Cerep1.4x-9.1x-
Prestige Biologics18.2x-(40.4x)-
Bioton1.4x-7.8x-
Rani Therapeutics34.7x21.1x(1.5x)-
ProMIS Neurosciences--(0.7x)-
Nanexa21.4x-186.2x-

This data is available for Pro users. Sign up to see all Ryvu Therapeutics competitors and their valuation data.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Ryvu Therapeutics

When was Ryvu Therapeutics founded?Ryvu Therapeutics was founded in 2007.
Where is Ryvu Therapeutics headquartered?Ryvu Therapeutics is headquartered in Poland.
How many employees does Ryvu Therapeutics have?As of today, Ryvu Therapeutics has over 294 employees.
Is Ryvu Therapeutics publicly listed?Yes, Ryvu Therapeutics is a public company listed on Warsaw Stock Exchange.
What is the stock symbol of Ryvu Therapeutics?Ryvu Therapeutics trades under RVU ticker.
When did Ryvu Therapeutics go public?Ryvu Therapeutics went public in 2011.
Who are competitors of Ryvu Therapeutics?Ryvu Therapeutics main competitors include Rallybio, PolyPid, Eurofins-Cerep, Prestige Biologics, Bioton, Rani Therapeutics, ProMIS Neurosciences, Nanexa, Laboratorios Richmond, Ensol Biosciences.
What is the current market cap of Ryvu Therapeutics?Ryvu Therapeutics' current market cap is $94M.
What is the current revenue of Ryvu Therapeutics?Ryvu Therapeutics' last 12 months revenue is $32M.
What is the current revenue growth of Ryvu Therapeutics?Ryvu Therapeutics revenue growth (NTM/LTM) is 23%.
What is the current EV/Revenue multiple of Ryvu Therapeutics?Current revenue multiple of Ryvu Therapeutics is 2.9x.
Is Ryvu Therapeutics profitable?No, Ryvu Therapeutics is not profitable.
What is the current EBITDA of Ryvu Therapeutics?Ryvu Therapeutics has negative EBITDA and is not profitable.
What is Ryvu Therapeutics' EBITDA margin?Ryvu Therapeutics' last 12 months EBITDA margin is (43%).
What is the current EV/EBITDA multiple of Ryvu Therapeutics?Current EBITDA multiple of Ryvu Therapeutics is (6.8x).
What is the current FCF of Ryvu Therapeutics?Ryvu Therapeutics' last 12 months FCF is ($2M).
What is Ryvu Therapeutics' FCF margin?Ryvu Therapeutics' last 12 months FCF margin is (7%).
What is the current EV/FCF multiple of Ryvu Therapeutics?Current FCF multiple of Ryvu Therapeutics is (43.2x).
How many companies Ryvu Therapeutics has acquired to date?Ryvu Therapeutics hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Ryvu Therapeutics has invested to date?Ryvu Therapeutics hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Ryvu Therapeutics

Lists including Ryvu Therapeutics

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial